ThromboGenics is dedicated to developing and commercializing new treatments that address unmet clinical needs in ophthalmology and oncology.
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology therapies. The Company’s lead drug, JETREA® (ocriplasmin), is approved for symptomatic vitreomacular adhesion (VMA)/vitreomacular traction (VMT).
JETREA® (ocriplasmin) was approved by the US FDA in October 2012 for the treatment of symptomatic vitreomacular adhesion (VMA) and launched in January 2013. JETREA® was granted a permanent J-code, J7316, in the US in January 2014. In March 2012 ThromboGenics signed a strategic partnership with Alcon / Novartis for the commercialization of JETREA® outside the United States.
In Europe, JETREA® is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon launched JETREA® first in the UK and Germany in 2013 and the treatment is now also available in Finland, Denmark, Norway, Sweden, Benelux, France, Switzerland and Canada.
Different European Health Technology Assessments (HTAs) confirm the value of early intervention and cost-effectiveness of JETREA® :
• NICE (UK) has recommended reimbursement of JETREA®, acknowledging that JETREA® is an innovative treatment and represents a step-change in how patients
with VMT are currently managed early in the course of their disease – metamorphopsia highlighted.
• G-BA (Germany) confirmed the exceptional benefit appraisal JETREA® by IQWiG. G-BA concluded in its value assessment that JETREA® demonstrates
considerable therapeutic benefits for patients suffering from mild and moderate symptoms of VMT when compared with watchful waiting.
• In January 2014 the French HTA gave JETREA® a positive recommendation for reimbursement and hospital listing in France.
ThromboGenics is strategically focused on maxi-mizing the global opportunity for JETREA® by:
• Commercializing JETREA® in the US via its own commercial organization.
• Supporting Alcon’s commercialization of JETREA® outside the US.
• Further developing its JETREA® franchise via new formulations and indications:
– The prevention of Proliferative Diabetic Retinopathy (PDR) is the next target indication for JETREA®, with the aim of offering a more simple and early-stage
therapeutic solution and possible prevention of PDR.
• Accessing novel ophthalmic medicines to expand ThromboGenics’ ophthalmology franchise with a focus on diabetes – sourced via own research, joint
development/licensing deals and possibly acquisitions:
• ThromboGenics entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target
for the treatment of diabetic macular edema (DME).
• ThromboGenics will work together with Eleven Biotherapeutics to develop recombinant protein therapeutics that can modulate a pathway in diabetic eye diseases
• ThromboGenics is also further exploring anti-PlGF (Placental Growth Factor), also referred to as TB-403, for the treatment of oncology indications.